SCHEMBL3134616

SCHEMBL3134616

O=C=NC1(c2ccccc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.38
CYP2C9 P11712 1/20 0.38
KMT2A Q03164 1/20 0.38
AKR1C1 Q04828 1/20 0.36
OPRM1 P35372 2/20 0.35
OPRK1 P41145 1/20 0.35
OPRL1 P41146 1/20 0.35
PNMT P11086 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
ABCC8 Q09428 1/20 0.33
KCNJ11 Q14654 1/20 0.33
HDAC4 P56524 1/20 0.32
GAA P10253 1/20 0.32
MCOLN3 Q8TDD5 1/20 0.32
DPP4 P27487 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4322724 0.92 AKR1C1 (0.38) MEN1CYP2C9KMT2AAKR1C1OPRM1
SCHEMBL1313846 0.92 AKR1C1 (0.42) AKR1C1HDAC4GAAMCOLN3DPP4
SCHEMBL26916818 0.90 AKR1C1 (0.41) MEN1KMT2AAKR1C1OPRM1HDAC4
SCHEMBL5172372 0.87 OPRM1 (0.50) MEN1CYP2C9KMT2AOPRM1
SCHEMBL11079809 0.87 MEN1 (0.53) MEN1CYP2C9KMT2AAKR1C1OPRM1
SCHEMBL23248029 0.87 ALDH1A1 (0.39) MEN1CYP2C9KMT2AGAA
SCHEMBL736092 0.86 POLB (0.39) MEN1CYP2C9KMT2AABCC8KCNJ11
SCHEMBL10936488 0.85 AKR1C1 (0.38) MEN1KMT2AAKR1C1OPRM1HDAC4
Ethylene SCHEMBL11091539 0.84 MEN1 (0.50) MEN1CYP2C9KMT2AAKR1C1GAA
SCHEMBL26916732 0.82 KEAP1 (0.32) MEN1CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674842-B2 Phase change inks containing curable isocyanate-derived compounds and phase change inducing components XEROX CORPORATION (US) 2010-03-09 US claimed
US-7541406-B2 Phase change inks containing curable isocyanate-derived compounds XEROX CORPORATION (US) 2009-06-02 US claimed
US-20070123642-A1 Phase change inks containing curable isocyanate-derived compounds XEROX CORPORATION 2007-05-31 US claimed
US-20070120909-A1 Phase change inks containing curable isocyanate-derived compounds and phase change inducing components XEROX CORPORATION 2007-05-31 US claimed
EP-0179254-B1 4,5-Dihydro-4-oxo-2- [(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof PENNWALT CORPORATION (US) 1989-03-29 EP claimed
EP-0237028-A1 N-(phenyl) or n-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4, (substituted phenyl) amino-3-furancarboxamide derivatives PENNWALT CORPORATION (US) 1987-09-16 EP claimed
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 US disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 EP disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 WO disclosed
US-6998390-B2 Oxolide antibacterials ABBVIE INC. 2006-02-14 US disclosed
EP-1579864-A1 Oxolide antibacterials ABBOTT LABORATORIES (US) 2005-09-28 EP disclosed
EP-1499326-A1 OXOLIDE ANTIBACTERIALS Abbott Laboratories (US) 2005-01-26 EP disclosed
US-20040014688-A1 Oxolide antibacterials ABBVIE INC. 2004-01-22 US disclosed
WO-2003090760-A1 OXOLIDE ANTIBACTERIALS ABBOTT LABORATORIES (US) 2003-11-06 WO disclosed
EP-0179254-B1 4,5-Dihydro-4-oxo-2- [(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof PENNWALT CORPORATION (US) 1989-03-29 EP disclosed
US-4614810-A MICROBIOCIDES PENNWALT CORPORATION (US) 1986-09-30 US disclosed
EP-0179254-A1 4,5-Dihydro-4-oxo-2- [(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof PENNWALT CORPORATION (US) 1986-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 MEN1 1124/4885CYP2C9 2725/4885KMT2A 3804/4885
US-20040014688-A1 Oxolide antibacterials OGFOD1, PGLS, OXER1 MEN1 1879/4885CYP2C9 48/4885KMT2A 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.